M easurement of lactate in human blood was first described by Scherer in 1843 when he described a lethal case of fulminant septic shock due to puerperal fever in a young woman (1) . Blood lactate monitoring is performed frequently in critically ill patients, usually aiming to detect tissue hypoxia (2) . However, other processes not related to tissue hypoxia and subsequent anaerobic metabolism can also result in increased blood lactate levels (3), complicating clinical interpretation and therapy in cases of raised lactate levels. The use of blood lactate monitoring remains controversial, which is reflected by its variable clinical use in different hospitals worldwide: Some hospitals routinely measure it whereas others hardly do so. Because the clinical benefit of blood lactate monitoring in critically ill patients has never been subjected to rigorous clinical evaluation, the question remains: Should we routinely monitor lactate in the critically ill and if so, when should we measure it? What would be the therapeutic consequences? and Would this improve patient outcome? To address these controversies, we performed a systematic health technology assessment (HTA) (4 -6) , which includes eight key questions (6) ( Table 1) .
METHODS

Data Sources
PubMed and other databases of English and non-English language literature (up to April 2008) were used: the Cochrane CEN-TRAL Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, the HTA Database, and NHS Economic Evaluation Database. Information on ongoing clinical trials was derived from the U.S. National Institutes of Health Web site (http:// www.clinicaltrials.gov).
Study Selection
We performed a systematic search for lactate (Medical Subject Heading ͓MeSH͔ terms "lactic acid" or "lactic acidosis"), in combination with critically ill patients as the target patient population (MeSH terms "intensive care units," "critical care," "critical illness," "hospital emergency service," "emergency medicine," or "postoperative care"). References of retrieved literature were reviewed manually for additional relevant material.
Out of the retrieved information, two reviewers (T.C.J. and J.vB.) independently selected studies to be included in this HTA on the basis of relevance for answering the eight key questions. Disagreements were resolved by consensus. General exclusion criteria were: no original research, case reports, and articles describing D-lactate or lactate concentration in other fluids than whole blood or plasma.
For each key question (Table 1) , separate inclusion criteria were defined.
Question I
To evaluate how accurate lactate measurement is in ideal controlled conditions, we first included studies that evaluated the accuracy of the measurement itself by comparison with a gold standard (arterial blood as reference site and central hospital laboratory as reference technique) and that used the Bland-Altman method for assessing agreement (7) .
To evaluate the diagnostic performance of lactate measurement, we subsequently included studies that investigated the anaerobic and/or aerobic etiology of hyperlactatemia. Because the etiology is complex and we could not find consensus definitions of gold standards for comparison, we did not define specific methodologic or statistical requirements.
Question II
In this step, we focused on the use of lactate as a prognostic tool. Because mortality is the most important and least subjective end point, we restricted inclusion to studies that used mortality as the primary end point and that provided sufficient information to construct 2 ϫ 2 contingency tables or area under the receiver operating characteristic curve.
Question III
We included studies on the association between blood lactate levels and other acid-base variables. Due to space limitations, we did not include studies on the prognostic value of these acid-base variables.
Question IV
We included studies evaluating the effect of blood lactate monitoring on healthcare workers' confidence.
Question V
We included studies that evaluated alterations in treatment following implementation of blood lactate monitoring protocols. We also included professional guidelines providing recommendations on blood lactate monitoring in critically ill patients.
Question VI
We included studies that combined the measurement of lactate levels with a treatment algorithm to provide benefit to the patient. Most studies focused on oxygen delivery (Ḋ O 2 ) therapy, which we classified in increasing order of importance: For question VI, studies evaluating preand intraoperative interventions were excluded to increase homogeneity.
Question VII
To estimate whether you could experience the same benefits in your own emergency department (ED) or intensive care unit (ICU), you need to know whether the demographics of your patient population are comparable, whether you have an equally educated and organized team, and whether you have similar access to facilities and equipment. For this question, we were not able to define specific criteria. Instead, we assessed subjectively external validity of the studies selected in steps I to VI.
Question VIII
We included studies evaluating costs or cost-effectiveness of blood lactate monitoring.
RESULTS
The results of the search and selection process are described in Figure 1 .
I. Does It Perform Well in the Laboratory?
Accuracy of Lactate Masurement
Device. Using the hospital's standard laboratory as the reference method, the selected studies generally reported small biases with clinically acceptable limits of agreement for point-of-care blood gas analyzers including the following: Nova Stat Profile 7,10, ultra, Nova Biomedical, Waltham, MA (8 -10); Chiron Diagnostics, 865 series, Fernwald, Germany/ Medfield, MA (11) (12) (13) (14) ; and Radiometer ABL 725, Radiometer Medical A/S, Bronshoj, Denmark (15) ; and the following handheld devices: Accusport/trend, Roche Diagnostics, Mannheim, Germany (9 -11, 16); i-STAT CG4ϩ, East Windsor, NJ (15) ; and Lactate Pro, ARKRAY, Kyoto, Japan (17). Lactate plus (Nova Biomedical, Waltham, MA) produced higher lactate values than the reference method (15, 17) .
Compartment. Although some described slightly higher peripheral venous (18) or capillary levels (11), most investigators found satisfactory agreement comparing capillary (16, 19, 20) , venous (21), or central/mixed venous (22-24) levels with arterial levels as reference. Sample handling: Ongoing in vitro glycolyis was reported to occur after blood sampling, resulting in erroneous elevation of lactate levels (25), particularly in case of leukocytosis or high hematocrit (26). Analysis within 15 mins or storage Ͻ4°C was suggested for avoiding this.
Exogenous Factors. Infusion of Ringer's lactate did not hamper accuracy (27), provided that a blood sample was drawn from a catheter that was adequately cleared from Ringer's lactate (28). Another study showed that the most commonly used critical care drugs neither affected the accuracy (29). Finally, renal replacement therapy eliminated only negligible amounts of lactate and consequently did not interfere with lactate monitoring (30). However, lactate-containing buffer solutions were able to induce transient hyperlactatemia (31-33).
Etiology of Hyperlactatemia
Anaerobic Hyperlactatemia
Systemic Oxygen Imbalance. Traditionally, hyperlactatemia is associated with tissue hypoxia. The causal relationship has been confirmed by experimental (34 -36) and clinical (2) studies: When reducing the components of systemic Ḋ O 2 until oxygen demand could no longer be met, and oxygen consumption was limited by Ḋ O 2 , this coincided with a sharp increase in lactate levels.
Several other observations also pointed to an anaerobic origin of hyper- 
Aerobic Hyperlactatemia
Selected studies demonstrated that other mechanisms than tissue hypoxia can also account for hyperlactatemia. We found the following aerobic mechanisms:
• Increased aerobic glycolysis, resulting in amounts of pyruvate that exceed the pyruvate dehydrogenase capacity. Such enhanced glycolysis can be triggered by cytokine-mediated uptake of glucose (44, 45) or catecholamine-stimulated increased Na-K-pump activity (46 -51), which was supported by a study of Levy et al in septic shock patients, where antagonizing the Na-K-pump completely stopped muscle lactate overproduction (3).
• Mitochondrial dysfunction (52) (53) (54) .
• Impaired activity of pyruvate dehydrogenase, essential for the conversion of pyruvate into acetyl coenzyme A. This enzyme is inhibited in septic conditions (55, 56) and increasing its activity with dichloroacetate reduces significantly blood lactate levels (57) . Thiamin deficiency (beriberi disease) inhibits pyruvate dehydrogenase activity and can cause hyperlactatemia (58).
• Liver dysfunction (59 -62) and liver surgery (63) . Reduced lactate clearance was also reported post cardiac surgery (64) and in sepsis (65, 66) , where it was shown to predict poor outcome (67 
II. Does It Provide Important Information in a Number of Clinical Situations?
We selected studies on the prognostic value of hyperlactatemia in many different critical care conditions, the ED (Table 2 ) and the ICU (Table 3 ). In the ED setting, area under the receiver operating characteristic curve for mortality varied from 0.67 (81) to 0.98 (82) , which indicates moder- ate-to-excellent prognostic accuracy. In the ICU setting, area under the receiver operating characteristic curve varied from 0.53 (83) and 0.58 (84) to 0.86 (85) , which indicates poor-to-good prognostic performance.
To answer the question whether a hyperlactatemic patient will die, which is what clinicians want to know when individually assessing patients, the positive predictive value or posttest probability is important. In some of our selected studies, positive predictive values for death in case of abnormal lactate levels (Ͼ2.0 -2.5 mmol/l) were very low (4%-15% (81, 86, 87) . However, comparison of the pretest probability (which is the study population mortality rate) with the posttest probability determines the value that lactate can add in risk-stratification: from our selected studies, it becomes clear that lactate generally increased the ability to predict nonsurvival, both in the ED and in the ICU setting.
None of the studies took into account that the real pretest probability not only depends on the mortality rate but also on the clinicians' ability to estimate risk, using all other available clinical parameters. Some authors therefore called for a future study that captures clinicians' estimates for probability of death before lactate measurement to evaluate the capacity to influence clinical practice decisions (88).
III. Is There a Relationship Between Lactate Levels and Metabolic Acidosis?
The level of lactate may be estimated from other acid-base variables. However, there was no clinically important relationship between lactate and pH or base excess (89 -94) , although one study showed that base excess could predict hyperlactatemia (95) . Accuracy of the anion gap for screening for hyperlactatemia was generally poor (96 -99) , but this varied to reasonably accurate (95) . Other studies showed that lactate was only responsible for a minor percentage of metabolic acidosis in critically ill patients (93, 100 -103) . Furthermore, lactate or nonlactate etiologies of metabolic acidosis are associated with different mortality rates (89, 104) . Therefore, although hyperlactatemia has often been associated with the presence of a metabolic acidosis (lactic acidosis), this relationship seemed not straightforward at all. Because the conversion of pyruvate to lactate does not directly result in production of Hϩ ions, it was hypothesized that only if the Hϩ ions generated during the hydrolysis of adenosine triphosphate cannot be recycled in the mitochondria, i.e., in anaerobic conditions, acidosis coincides with hyperlactatemia (105) . Following this hypothesis, it has been argued that the presence of metabolic acidosis can be used to distinguish aerobic from anaerobic hyperlactatemia (106) . The weak correlation between hyperlactatemia and metabolic acidosis has also been explained from another point of view. In Stewart's acid-base classification, three independent variables control pH: strong ion difference; PCO 2 ; and the sum of the weak acids and proteins in plasma (107) . An increased lactate level reduces strong ion difference, which has an acidifying effect. However, in Stewart's model, this does not necessarily result in acidosis because other simultaneous alterations in strong ion difference, changes in the amount of weak acids and proteins, or changes in PCO 2 can all influence pH (93, 100).
IV. Does It Increase Healthcare Workers' Confidence?
Information provided by a parameter may lead to increased confidence among healthcare providers. Although questionable if no other clinical end point (mortality, morbidity, costs) is improved, increased confidence might be an important goal when decisions are made in conditions of uncertainty in critical care. For instance, in a trial on perioperative pulse oximetry, the rate of complications was not reduced, but 80% of the anesthesiologists felt more secure when using a pulse oximeter (108) . It seems likely that lactate determinations could increase workers' confidence because rapidly available and definite end points of resuscitation are scarce. An observation that the nursing team expressed a positive attitude toward implementation of a hemodynamic protocol that included frequent lactate measurements indirectly supports this (109) . However, we were not able to find a study that specifically evaluated the effect on healthcare workers' confidence.
V. Are Therapeutic Decisions Altered as a Result of Blood Lactate Levels?
In studies on treatment alterations post implementation of lactate monitoring, hyperlactatemia was interpreted as a result of anaerobic conditions due to systemic oxygen imbalance and this was a trigger to increase Ḋ O 2 or decrease oxygen demand (110 -113) . This included administration of fluids, inotropic agents, red blood cell transfusion, mechanical ventilation, paralytic agents, sedatives, and analgesics. In the only randomized controlled study in which measurement of lactate was compared with not measuring lactate, more fluids and inotropes were administered in the lactate group (114) .
We also selected professional guidelines: the Surviving Sepsis Campaign recommends the use of lactate as a trigger for early goal-directed therapy (Ն4 mmol/L) (115) . The Clinical Practice Guideline concerning trauma resuscitation recommends lactate as a resuscitation end point but acknowledged that evidence of improved survival of such strategy has not been shown (116) . Finally, the International Consensus Conference 2006 on hemodynamic monitoring and management of patients in shock also stresses the lack of clinical trials investigating the clinical value of incorporating lactate in a treatment protocol (117) .
VI. Does Application of Blood Lactate Monitoring Result in Benefit to Patients?
As monitoring itself will not change outcome, an integrated treatment algorithm has to provide the benefit to patients. This has to be aimed at the conditions leading to hyperlactatemia rather than at reduction of lactate levels alone. For instance, improving pyruvate metabolism by administration of dichloroacetate decreased lactate levels (57) but this was not associated with a clinical benefit. Another study showed that bicarbonate therapy did not improve hemodynamic variables in patients with lactic acidosis (118) . These observations indicate that the detrimental outcome associated with hyperlactatemia is more likely to be determined by the underlying cause than by the hyperlactatemia itself.
We selected four observational studies evaluating implementation of a lactateguided Ḋ O 2 therapy algorithm (Table 4) . Lactate levels decreased significantly during lactate-guided therapy (110, 111, 113) , which coincided with an increase in ScvO 2 in one study (110) . Patients who responded with normalization of lactate had lower mortality than those who remained hyperlactatemic (111, 113) . One observational study made a comparison with a historical control group and found lower mortality post implementation of a lactate-guided Ḋ O 2 therapy algorithm (112) .
We selected nine randomized controlled studies that evaluated goal-directed Ḋ O 2 therapy, which was not specifically lactateguided, but that used lactate levels as a primary or secondary end point (Table 5) . Out of the five studies that showed a positive outcome (40, 119 -122) , three studies reported a decrease of lactate in the intervention group compared with the control group (40, 120, 122) .
However, we found only one completed randomized controlled study evaluating goal-directed Ḋ O 2 therapy that included a lactate-guided group and a nonlactateguided group (Table 6 ). This study in a postcardiac surgery population showed a reduction in length of stay in the lactateguided group (114) . Two studies are currently ongoing.
VII. Can You Expect a Similar Benefit in Your Own Setting?
To answer this question, the external validity of the previously selected studies needs to be determined. Given that lactate measurement is generally considered as easy and accurate, that it is commonly available worldwide, and given that evidence on the prognostic value of hyperlactatemia has been very consistent and applies to many different populations, it is clear that lactate can be used as a prognostic marker in your own setting. However, the value of lactate as a therapeutic tool remains unclear.
VIII. Are the Expected Benefits Worth the Costs?
A handheld lactate device, such as Accutrend (Roche, Basel, Switzerland) costs around €200 and a test strip costs €2. The price of a blood gas analyzer is around €30,000 and total costs per sample are €2 (10). In a German study, total costs were lowest with €1 per measurement, using the handheld device, followed by €2 using the blood gas analyzer (Chiron 865 series, Novartis Vaccines and Diagnostics, Emeryville, CA), and €5 when using the central hospital's laboratory (11) . In the Netherlands, external budget costs per measurement are €12. We did not find a study on the cost-effectiveness of lactate monitoring. Although costs of lactate measurement itself are relatively low, costs of subsequent therapeutic consequences and use of health care resources are unknown.
DISCUSSION
We found that lactate performs well in the laboratory: The measurement itself is accurate and clinicians at the bedside can trust the numerical value of lactate levels they collect. However, sufficient understanding of anaerobic and aerobic mechanisms of production and clearance is essential for the correct interpretation of hyperlactemia. Although the prognostic accuracy of lactate varied considerably, lactate generally increased the ability to predict nonsurvival, both in the ED and ICU. The consistency of this finding means that lactate certainly has a place in the riskstratification of critically ill patients. Because of the weak correlation between hyperlactatemia and metabolic acidosis, lactate should be directly measured instead of estimated from other acid-base variables. Furthermore, lactic or nonlactic metabolic acidoses are associated with different mortality.
Concerning the clinical impact of lactate monitoring, it seems likely that it can increase healthcare workers' confidence although we were not able to find studies on this topic. Lactate monitoring has the potential to alter therapeutic decisions as hyperlactatemia in critically ill patients is often interpreted as a result of systemic oxygen imbalance, triggering goal-directed Ḋ O 2 therapy. Indirect evidence supports the therapeutic benefit of lactate monitoring. However, there is a lack of clinical trials investigating the clinical value of lactatedirected therapy; the only single-center clinical trial advocating its efficacy was performed in postcardiac surgery patients and this cannot easily be extrapolated to other critical care populations. In addition, although costs of lactate measurement itself are relatively low, cost-effectiveness of lactate measurements is unknown.
Strengths of our study include the systematic search and selection strategy and the eight-question format that provides a complete and clinically relevant assessment of the real value of lactate monitoring. Our study also has limitations. We did not perform a methodologic quality assessment of the selected studies. The variety of study designs was too large for a single methodologic quality score. We did not perform a meta-analysis, which would have been valuable when evaluating prognostic accuracy or efficacy of lactate-directed therapy. However, the studies were far too heterogeneous (large variations in patient categories, mortality rates, lactate cutoff values, and timing of measurements or interventions). Finally, the results of this study need to be interpreted in the light of the search and selection criteria, and we might have missed information.
CONCLUSIONS
Based on the results of this systematic HTA, blood lactate monitoring is recommended in critical care settings as the ED and ICU because it clearly has a place in the risk-stratification of critically ill patients. However, it is unknown whether the routine use of lactate as a resuscitation end point improves outcome. This warrants randomized controlled studies on the efficacy of lactatedirected therapy.
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